Associate Director, Clinical Development & Medical Affairs (CDMA) Operations & Innovation

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling:  ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations.  

On August 8th 2025, the U.S. Food and Drug Administration (FDA)  accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant.

 

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.

#TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.

 

For more information, please visit www.arvinas.com. 

Position Summary

The Associate Director, Clinical Development & Medical Affairs Operations plays an integral role in supporting the Medical Affairs organization. This position will be responsible for operational management of various projects and programs within Medical Affairs, and in partnership with cross-functional stakeholders.

This position reports to the Executive Director, Medical Affairs Operations, and may be located at our headquarters in New Haven, CT or may be performed remotely from a location within the U.S.

Principal Responsibilities

Key responsibilities of this role include, but are not limited to:

• Provides operational support to Medical Affairs department and projects, including managing project timelines and budget
• Supports scientific publications operations, including publication tracking and reporting, author and agency coordination, document and journal submission management, compliance reviews, and maintenance of the Medical Affairs publications site
• Assists in the planning and execution of congress activities
• Assists in the planning and execution of Advisory Boards to include FMV assessments, tracking consultant agreements, and ensuring proper documentation
• Coordinates Medical Review Committee process for review of scientific exchange materials
• Manages the contra